Cumulative HPV incidence over 1 year, persistence and clearance among 97 women with results available at enrolment and 12 months, by HPV genotype
| Control (N=24 women) | Vaccine (N=73 women) | Total (N=97 women) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infected at visit 1 | Persistent* | Cleared* | New† | Infected at visit 1 | Persistent* | Cleared* | New† | Infected at visit 1 | Persistent* | Cleared* | New† | |
| High risk | ||||||||||||
| HPV-16 | 3 | – | 3 (100%) | 1 (4.8%) | 11 | 4 (36.4%) | 7 (63.6%) | 0 (–) | 14 | 4 (28.6%) | 10 (71.4%) | 1 (1.2%) |
| HPV-18 | 1 | – | 1 (100%) | 1 (4.4%) | 0 | – | – | 1 (1.4%) | 1 | – | 1 (100%) | 2 (2.1%) |
| HPV-31 | 0 | – | – | 0 (–) | 3 | 1 (33.3%) | 2 (66.7%) | 3 (4.3%) | 3 | 1 (33.3%) | 2 (66.7%) | 3 (3.2%) |
| HPV-33 | 1 | – | 1 (100%) | 0 (–) | 2 | 1 (50.0%) | 1 (50.0%) | 2 (2.8%) | 3 | 1 (33.3%) | 2 (66.7%) | 2 (2.1%) |
| HPV-35 | 1 | 1 (100%) | – | 0 (–) | 4 | 2 (50.0%) | 2 (50.0%) | 6 (8.7%) | 5 | 3 (60.0%) | 2 (40.0%) | 6 (6.5%) |
| HPV-39 | 1 | – | 1 (100%) | 1 (4.4%) | 7 | 1 (14.3%) | 6 (85.7%) | 8 (12.1%) | 8 | 1 (12.5%) | 7 (87.5%) | 9 (10.1%) |
| HPV-45 | 4 | – | 4 (100%) | 0 (–) | 13 | 1 (7.7%) | 12 (92.3%) | 3 (5.0%) | 17 | 1 (5.9%) | 16 (94.1%) | 3 (3.8%) |
| HPV-51 | 2 | 1 (50.0%) | 1 (50.0%) | 2 (9.1%) | 3 | 1 (33.3%) | 2 (66.7%) | 9 (12.9%) | 5 | 2 (40.0%) | 3 (60.0%) | 11 (12.0%) |
| HPV-52 | 1 | 1 (100%) | – | 1 (4.4%) | 7 | 2 (28.6%) | 5 (71.4%) | 4 (6.1%) | 8 | 3 (37.5%) | 5 (62.5%) | 5 (5.6%) |
| HPV-56 | 2 | – | 2 (100%) | 1 (4.6%) | 0 | – | – | 3 (4.1%) | 2 | – | 2 (100%) | 4 (4.2%) |
| HPV-58 | 3 | 1 (33.3%) | 2 (66.7%) | 1 (4.8%) | 9 | 3 (33.3%) | 6 (66.7%) | 0 (–) | 12 | 4 (33.3%) | 8 (66.7%) | 1 (1.2%) |
| HPV-59 | 2 | 1 (50.0%) | 1 (50.0%) | 0 (–) | 2 | – | 2 (100%) | 3 (4.2%) | 4 | 1 (25.0%) | 3 (75.0%) | 3 (3.2%) |
| HPV-68 | 2 | 2 (100%) | – | 1 (4.6%) | 2 | 1 (50.0%) | 1 (50.0%) | 6 (8.5%) | 4 | 3 (75.0%) | 1 (25.0%) | 7 (7.5%) |
| All high risk infections‡ | 23 | 7 (30.4%) | 16 (69.6%) | 9 | 63 | 17 (27.0%) | 46 (73.0%) | 48 | 86 | 24 (27.9%) | 62 (72.1%) | 57 |
| Low risk | ||||||||||||
| HPV-6 | 2 | – | 2 (100%) | 3 (13.6%) | 4 | 1 (25.0%) | 3 (75.0%) | 3 (4.4%) | 6 | 1 (16.7%) | 5 (83.3%) | 6 (6.6%) |
| HPV-11 | 0 | – | – | 0 (–) | 1 | – | 1 (100%) | 4 (5.6%) | 1 | – | 1 (100%) | 4 (4.2%) |
| HPV-26 | 1 | – | 1 (100%) | 1 (4.4%) | 3 | – | 3 (100%) | 2 (2.9%) | 4 | – | 4 (100%) | 3 (3.2%) |
| HPV-40 | 2 | – | 2 (100%) | 1 (4.6%) | 3 | – | 3 (100%) | 2 (2.9%) | 5 | – | 5 (100%) | 3 (3.3%) |
| HPV-42 | 1 | – | 1 (100%) | 0 (–) | 4 | 1 (25.0%) | 3 (75.0%) | 3 (4.4%) | 5 | 1 (20.0%) | 4 (80.0%) | 3 (3.3%) |
| HPV-53 | 1 | 1 (100%) | – | 5 (21.7%) | 10 | 2 (20.0%) | 8 (80.0%) | 4 (6.4%) | 11 | 3 (27.3%) | 8 (72.7%) | 9 (10.5%) |
| HPV-54 | 5 | 3 (60.0%) | 2 (40.0%) | 2 (10.5%) | 3 | 1 (33.3%) | 2 (66.7%) | 4 (5.7%) | 8 | 4 (50.0%) | 4 (50.0%) | 6 (6.7%) |
| HPV-55 | 2 | 1 (50.0%) | 1 (50.0%) | 1 (4.6%) | 6 | 1 (16.7%) | 5 (83.3%) | 2 (3.0%) | 8 | 2 (25.0%) | 6 (75.0%) | 3 (3.4%) |
| HPV-61 | 2 | 1 (50.0%) | 1 (50.0%) | 2 (9.1%) | 5 | 2 (40.0%) | 3 (60.0%) | 5 (7.4%) | 7 | 3 (42.9%) | 4 (57.1%) | 7 (7.8%) |
| HPV-62 | 0 | – | – | 1 (4.2%) | 4 | 2 (50.0%) | 2 (50.0%) | 3 (4.4%) | 4 | 2 (50.0%) | 2 (50.0%) | 4 (4.3%) |
| HPV-64 | 0 | – | – | 0 (–) | 1 | – | 1 (100%) | 2 (2.8%) | 1 | – | 1 (100%) | 2 (2.1%) |
| HPV-66 | 3 | 2 (66.7%) | 1 (33.3%) | 1 (4.5%) | 4 | – | 4 (100%) | 6 (8.7%) | 7 | 2 (28.6%) | 5 (71.4%) | 7 (7.8%) |
| HPV-67 | 2 | – | 2 (100%) | 1 (4.6%) | 2 | – | 2 (100%) | 6 (8.5%) | 4 | – | 4 (100%) | 7 (7.5%) |
| HPV-70 | 1 | – | 1 (100%) | 1 (4.4%) | 0 | – | – | 1 (1.4%) | 1 | – | 1 (100%) | 2 (2.1%) |
| HPV-73 | 1 | – | 1 (100%) | 1 (4.4%) | 1 | – | 1 (100%) | 1 (1.4%) | 2 | – | 2 (100%) | 2 (2.1%) |
| HPV-81 | 3 | 1 (33.3%) | 2 (66.7%) | 1 (4.8%) | 1 | – | 1 (100%) | 3 (4.2%) | 4 | 1 (25.0%) | 3 (75.0%) | 4 (4.3%) |
| HPV-82 | 1 | – | 1 (100%) | 0 (–) | 3 | 1 (33.3%) | 2 (66.7%) | 2 (2.9%) | 4 | 1 (25.0%) | 3 (75.0%) | 2 (2.2%) |
| HPV-83 | 1 | 1 (100%) | – | 2 (8.7%) | 2 | 1 (50.0%) | 1 (50.0%) | 4 (5.6%) | 3 | 2 (66.7%) | 1 (33.3%) | 6 (6.4%) |
| HPV-84 | 4 | 1 (25.0%) | 3 (75.0%) | 0 (–) | 3 | – | 3 (100%) | 5 (7.1%) | 7 | 1 (14.3%) | 6 (85.7%) | 5 (5.6%) |
| CP6108 | 1 | 1 (100%) | – | 1 (4.4%) | 8 | 3 (37.5%) | 5 (62.5%) | 3 (4.6%) | 9 | 4 (44.4%) | 5 (55.6%) | 4 (4.6%) |
| All low risk infections‡ | 33 | 12 (36.4%) | 21 (63.6%) | 24 | 68 | 15 (22.1%) | 53 (77.9%) | 65 | 101 | 27 (26.7%) | 74 (73.3%) | 89 |
*Among those infected with that serotype at visit 1 (enrolment).
†Cumulative incidence among those uninfected with that serotype at enrolment.
‡Total number of genotype-specific infections among 97 women (24 in control and 73 in vaccine arm).
HPV, human papillomavirus.